M. Weniger Et Al. , "Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.," Surgical oncology , vol.35, pp.285-297, 2020
Weniger, M. Et Al. 2020. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.. Surgical oncology , vol.35 , 285-297.
Weniger, M., Moir, J., Damm, M., Maggino, L., Kordes, M., Rosendahl, J., ... Ceyhan, G.(2020). Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.. Surgical oncology , vol.35, 285-297.
Weniger, M Et Al. "Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.," Surgical oncology , vol.35, 285-297, 2020
Weniger, M Et Al. "Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.." Surgical oncology , vol.35, pp.285-297, 2020
Weniger, M. Et Al. (2020) . "Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.." Surgical oncology , vol.35, pp.285-297.
@article{article, author={M Weniger Et Al. }, title={Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.}, journal={Surgical oncology}, year=2020, pages={285-297} }